A Genome-Wide Association Study of Chemotherapy-Induced Alopecia in Breast Cancer Patients

    September 2013 in “ Breast cancer research ”
    Suyoun Chung, Siew‐Kee Low, Hitoshi Zembutsu, Atsushi Takahashi, Michiaki Kubo, Mitsunori Sasa, Yusuke Nakamura
    TLDR A specific gene variant is linked to a higher risk of hair loss from chemotherapy in breast cancer patients.
    The genome-wide association study (GWAS) investigated genetic risk factors for chemotherapy-induced alopecia in breast cancer patients, involving 303 individuals with grade 2 alopecia and 880 without hair loss. The study identified a significant SNP (rs3820706 in CACNB4) associated with a higher risk of alopecia (P = 8.13 × 10^-9, OR = 3.71). A weighted genetic risk scoring (wGRS) system classified patients into risk groups, with the highest risk group having a 443 times higher risk of alopecia from antimicrotubule agents compared to the lowest risk group. These findings provided insights into the molecular mechanisms of chemotherapy-induced alopecia and could aid in developing preventive or therapeutic interventions, although further validation with independent samples was needed.
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results

    Related Community Posts Join

    6 / 50 results

      community The perfect reverse reverse hair-loss nuclear stack for those who feel left out

      in Satire  415 upvotes 1 month ago
      A satirical discussion on intentionally inducing hair loss using harmful habits and substances like cigarettes, junk food, anabolic steroids, and stress. The conversation humorously suggests extreme measures like chemotherapy and hydrofluoric acid, while also mentioning the ineffectiveness of sulfates and pumpkin seed oil in hair loss prevention.

      community Realistically, how much PP405 will cost?

      in Treatment  30 upvotes 8 months ago
      PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

    Related Research

    2 / 2 results